NeoGenomics, Inc. Hits New 52-Week High at $13.87

NeoGenomics, Inc., a small-cap player in the Pharmaceuticals & Biotechnology sector, has reached a significant milestone by hitting a new 52-week high of USD 13.87 on June 25, 2026. This achievement marks a notable increase from its 52-week low of USD 4.72, reflecting a substantial upward movement in the stock's performance over the past year. Despite a 1-year performance of 3.08%, which lags behind the S&P 500's 20.77%, NeoGenomics continues to navigate its market position with a current market capitalization of USD 933 million. The company operates with a debt-to-equity ratio of 0.22, indicating a relatively low level of debt compared to its equity. However, it is important to note that NeoGenomics is currently loss-making, as reflected by its negative return on equity of -8.39% and a price-to-book ratio of 1.12. As NeoGenomics celebrates this new high, it underscores the company's ongoing developments within the competitive landscape of the pharmaceuticals and biotechnology industry.